undamentalytics Newsletter
Sign in

Nektar Therapeutics income statement

In fiscal 2025, Nektar Therapeutics reported revenue of $55.2m, down 43.9% on the year before, operating income of −$140m (a -253.7% margin) and net income of −$164m, or −$9.73 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue7215971811492012311653081,1931151531029290985555
Cost of revenue———————3031242119252234310—
Gross profit———————1352771,169931337770566855—
Research and development95108127149190148183204268400435409400218114121117132
General and administrative41414742414143445281991051239277776953
Operating income−95−28−124−141−120−16−29−113−60688−440−425−446−376−264−105−140−141
Interest expense1211101518181822222221700————
Income before tax−103−37−133−171−160−54−81−153−96683−440−444−523−365−276−119−164−162
Income tax−01102−111111013−0−0−00
Net income−103−38−134−172−162−54−81−154−97681−441−444−524−368−276−119−164−157
Diluted EPS−$1.11−$0.40−$17.85−$22.50−$1.40−$0.42−$0.61−$1.10−$0.62$3.78−$2.52−$2.49−$2.86−$1.97−$1.45−$8.68−$9.73−$6.47
Diluted shares (average)——8m8m8m8m9m9m10m12m12m12m12m12m13m14m17m24m
EBITDA−80−12−109−127−106−4−18−100−47697−429−413−433−364−257−101−139−140

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: NKTR vs TNGXNKTR vs SIGAGOSS vs NKTRIVVD vs NKTR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Nektar Therapeutics's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Nektar Therapeutics.